FARMERS & MERCHANTS TRUST Co OF LONG BEACH lowered its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,339 shares of the biopharmaceutical company’s stock after selling 2,643 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Pfizer were worth $2,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently added to or reduced their stakes in PFE. Moneta Group Investment Advisors LLC lifted its stake in Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Morgan Stanley increased its stake in Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 4.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 73,340,479 shares of the biopharmaceutical company’s stock worth $3,741,204,000 after buying an additional 3,216,573 shares in the last quarter. Norges Bank acquired a new position in shares of Pfizer in the fourth quarter worth $3,150,472,000. Finally, Bank of New York Mellon Corp increased its position in shares of Pfizer by 0.6% during the third quarter. Bank of New York Mellon Corp now owns 56,659,179 shares of the biopharmaceutical company’s stock worth $2,479,407,000 after acquiring an additional 317,858 shares during the period. 67.80% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The shares were purchased at an average cost of $38.58 per share, for a total transaction of $38,580.00. Following the completion of the purchase, the director now directly owns 6,000 shares in the company, valued at $231,480. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.05% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Pfizer Stock Down 0.3 %
PFE stock opened at $35.53 on Friday. The company has a market cap of $200.58 billion, a price-to-earnings ratio of 6.99, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a fifty day moving average price of $38.03 and a 200 day moving average price of $41.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.37 and a quick ratio of 1.11. Pfizer Inc. has a 12 month low of $35.35 and a 12 month high of $54.93.
Pfizer (NYSE:PFE – Free Report) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.23. The business had revenue of $18.28 billion during the quarter, compared to the consensus estimate of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The business’s quarterly revenue was down 28.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.62 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 3.35 earnings per share for the current year.
Pfizer Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be paid a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 4.62%. The ex-dividend date of this dividend is Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is presently 32.28%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
